Profile data is unavailable for this security.
About the company
Cytophage Technologies Ltd. is a Canadian biotechnology company focused on bacteriophage research, product development and commercialization. The Company’s business activity is to develop bacteriophages that will reduce and ultimately replace the use of antibiotics for illness prevention and treatment. Bacteriophages are viruses that only infect and kill bacteria. These natural killers of bacteria can overcome cellular or organism-level defenses. The Company is using de-risked and patented technology to advance products that harness the power of bacteriophages to combat bacterial infections affecting human health, animal health, and food security. Its products include FarmPhage, AviPhage, PhageFend, and BoviPhage. FarmPhage is a water-soluble phage solution for livestock. AviPhage is a poultry health product offered by the Company.
- Revenue in CAD (TTM)0.00
- Net income in CAD-4.57m
- Incorporated2019
- Employees--
- LocationCytophage Technologies Ltd200A-400 Fort Whyte WayOAK BLUFF R4G 0B1CanadaCAN
- Phone+1 (416) 214-4810
- Websitehttps://cytophage.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kane Biotech Inc | 574.87k | -1.95m | 7.20m | -- | -- | -- | -- | 12.52 | -0.0114 | -0.0214 | 0.0034 | -0.0047 | 0.173 | 1.30 | 2.42 | -- | -58.59 | -80.66 | -192.03 | -- | -16.60 | 44.47 | -338.70 | -257.96 | 0.7172 | -10.81 | 1.53 | -- | 1,296.75 | 4.21 | 30.71 | -- | -1.53 | -- |
| Cytophage Technologies Ltd | 0.00 | -4.57m | 9.72m | -- | -- | 7.67 | -- | -- | -0.0816 | -0.0816 | 0.00 | 0.0189 | 0.00 | -- | -- | -- | -98.03 | -- | -117.55 | -- | -- | -- | -- | -- | -- | -59.47 | 0.5422 | -- | -- | -- | -69.62 | -- | -- | -- |
| Pharmacielo Ltd | 2.83m | -6.42m | 13.03m | 268.00 | -- | -- | -- | 4.61 | -0.0356 | -0.0356 | 0.0156 | -0.0795 | 0.1994 | 1.71 | 4.10 | -- | -45.28 | -- | -- | -- | 3.13 | -- | -227.15 | -- | 0.0907 | -3.01 | 6.18 | -- | -- | -- | -- | -- | -- | -- |
